Ixazomib vs TQB3602
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: Proteasome · full Multiple Myeloma pipeline
Ixazomib
Marketed by Takeda Pharmaceutical Company and partners
NCT01564537 · Phase 3 · completed
Participants were randomly assigned and quadruple-blinded to ixazomib plus lenalidomide and dexamethasone or matching placebo plus lenalidomide and dexamethasone, with 360 and 362 participants, respectively. The hard clinical primary endpoint of independently assessed progression-free survival was met: median progression-free survival was 20.6 versus 14.7 months, with a statistically significant difference between groups (p=0.012).
Next expected readout: March 2027 · NCT04068597 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) (From randomization until PD or death (up to 52 months)): Progression Free Survival (PFS) (From randomization until PD or death (up to 52 months)): Ixazomib 17.4 months (95% CI 14.78 to 20.3) vs Placebo 9.4 months (95% CI 8.51 to 11.47) (met)
Result source: NCT02312258
TQB3602
Developed by Sino Biopharmaceutical
NCT04275583 · Phase 1 · status unknown
This is a small, open-label, single-arm, non-randomized dose-finding study designed to establish tolerability rather than to test clinical benefit, with no comparator arm and no blinding. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
These results cover the 25-patient dose-escalation phase; the study's dose-expansion phase is not included.
Reported efficacy
Dose-limiting toxicity (DLT) (Baseline up to 28 days): Twenty-five patients with relapsed/refractory multiple myeloma who had relapsed or failed at least 2 lines of therapy were enrolled in the dose-escalation phase. Two patients in the 7.0 mg dose group developed dose-limiting toxicities, giving a maximum tolerated dose of 6.0 mg. Any-grade adverse events occurred in 24 (96.0%) patients and grade >=3 adverse events in 13 (52.0%). Among 22 response-evaluable patients, 63.7% achieved stable disease or better.
Result source: NCT04275583
Results for Multiple Myeloma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Ixazomib | TQB3602 |
|---|---|---|
| PFS, median | 20.6 vs 14.7+5.9 vs placeboNCT0156453713 other results
| —Not reported |
| OS, median | 53.6 vs 51.6+2 vs placeboNCT015645376 other results
| —Not reported |
| ORR | 78.3% vs 71.5%+6.8 vs placeboNCT0156453710 other results
| —Not reported |
| VGPR or better | 48.1% vs 39%+9.1 vs placeboNCT015645372 other results
| —Not reported |
| MRD negativity | 59% vs 50%+9 vs placeboNCT018505243 other results
| —Not reported |
PFS, median
- Ixazomib
- 20.6 vs 14.7+5.9 vs placeboNCT01564537
13 other results
- 35.3 vs 21.8 NCT01850524
- 26.5 vs 21.3 NCT02181413
- 17.4 vs 9.4 NCT02312258
- 18.7 vs 9.3 NCT01564537
- 10.1 vs 9.6 NCT02312258
- 21.3 NCT03748953
- 7.1 vs 4.8 NCT03170882
- 29.0 vs 29.0 NCT03416374
- 5.2 NCT02477215
- 22.1 NCT02917941
- 23.5 NCT02046070
- 23 NCT02046070
- 14.2 NCT02046070
- TQB3602
- —Not reported
OS, median
- Ixazomib
- 53.6 vs 51.6+2 vs placeboNCT01564537
6 other results
- 64.8 vs 69.5 NCT02312258
- 42.2 vs 29.4 NCT01564537
- 46.9 vs 30.9 NCT01564537
- 37.3 vs 48.3 NCT02312258
- 18.8 NCT03170882
- 23.2 NCT02477215
- TQB3602
- —Not reported
ORR
- Ixazomib
- 78.3% vs 71.5%+6.8 vs placeboNCT01564537
10 other results
- 82% vs 80% NCT01850524
- 49% NCT02046070
- 63% NCT01864018
- 38% vs 41% NCT03170882
- 73.3% vs 71.8% NCT03416374
- 28% NCT02477215
- 84.4% NCT02917941
- 35% NCT02765854
- 35% NCT02765854
- 73% NCT02765854
- TQB3602
- —Not reported
VGPR or better
- Ixazomib
- 48.1% vs 39%+9.1 vs placeboNCT01564537
2 other results
- 50% NCT02917941
- 42.2% vs 43.6% NCT03416374
- TQB3602
- —Not reported
MRD negativity
- Ixazomib
- 59% vs 50%+9 vs placeboNCT01850524
3 other results
- 6% vs 3% NCT02312258
- 18% NCT02389517
- 31% NCT02389517
- TQB3602
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Ixazomib: 4 of 4 rows · TQB3602: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Ixazomib |
|---|---|
| Dropout rate | 28.1%a NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3 show 40 more results49.3%Ixazomib + LenDex NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 —Ixazomib + LenDex (Exposure ≥19 Cy NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 —Ixazomib+ LenDex (Exposure Up to 1 NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 — NCT03941860 · Phase 3 · combination · Multiple Myeloma · phase 3 18.5% NCT02181413 · Phase 3 n/a: no completion milestone NCT02312258 · Phase 3 — NCT03416374 · Phase 4 · registry result, not featured evidence · combination 0% NCT03748953 · Phase 3 · registry result, not featured evidence — NCT02619682 · Phase 2 · registry result, not featured evidence 3%Arm A (Ixazomib Citrate and Dexame NCT01415882 · Phase 2 · registry result, not featured evidence · combination 2.8%Arm B (Ixazomib Citrate and Dexame NCT01415882 · Phase 2 · registry result, not featured evidence · combination 0%Arm C (Higher-dose Ixazomib Citrat NCT01415882 · Phase 2 · registry result, not featured evidence · combination 10.8%Arm D (Ixazomib Citrate, Dexametha NCT01415882 · Phase 2 · registry result, not featured evidence · combination 0%Arm E (Ixazomib Citrate, Cyclophos NCT01415882 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneIxazomib Combination Therapy NCT02924272 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneIxazomib Monotherapy NCT02924272 · Phase 2 · registry result, not featured evidence · monotherapy 30%Arm I (Ixazomib Citrate, Lenalidom NCT02389517 · Phase 2 · registry result, not featured evidence · combination 22.7%Arm II (Lenalidomide) NCT02389517 · Phase 2 · registry result, not featured evidence 0% NCT02412228 · Phase 2 · registry result, not featured evidence · combination 0%Arm A (Ixazomib and Dexamethasone) NCT02765854 · Phase 2 · registry result, not featured evidence 0%Arm B (Ixazomib and Dexamethasone) NCT02765854 · Phase 2 · registry result, not featured evidence 0%Arm C (Ixazomib, Dexamethasone, Le NCT02765854 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone4 mg NCT03170882 · Phase 2 · registry result, not featured evidence · combination 14.3% NCT02440464 · Phase 2 · registry result, not featured evidence 70.6%4 mg + 25 mg + 40 mg NCT02917941 · Phase 2 · registry result, not featured evidence · combination 33.3%4 mg NCT02168101 · Phase 2 · registry result, not featured evidence 66.7%3 mg NCT02168101 · Phase 2 · registry result, not featured evidence 66.7%2.3 mg NCT02168101 · Phase 2 · registry result, not featured evidence 88.9%Ixazomib 4.0 mg + CYC 300 mg/m^2 + NCT02046070 · Phase 2 · registry result, not featured evidence · combination 89.7%Ixazomib 4.0 mg + CYC 300 mg/m^2 + NCT02046070 · Phase 2 · registry result, not featured evidence · combination 82.4%Ixazomib 4.0 mg + CYC 400 mg/m^2 + NCT02046070 · Phase 2 · registry result, not featured evidence · combination 95% NCT02499081 · Phase 2 · registry result, not featured evidence 0%4 mg NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination 0%3 mg NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination —90 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination 0%90 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination —80 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination 25%80 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination —70 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination 25%70 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —a NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3 show 40 more results—Ixazomib + LenDex NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 —Ixazomib + LenDex (Exposure ≥19 Cy NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 —Ixazomib+ LenDex (Exposure Up to 1 NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 — NCT03941860 · Phase 3 · combination · Multiple Myeloma · phase 3 — NCT02181413 · Phase 3 — NCT02312258 · Phase 3 — NCT03416374 · Phase 4 · registry result, not featured evidence · combination — NCT03748953 · Phase 3 · registry result, not featured evidence — NCT02619682 · Phase 2 · registry result, not featured evidence —Arm A (Ixazomib Citrate and Dexame NCT01415882 · Phase 2 · registry result, not featured evidence · combination —Arm B (Ixazomib Citrate and Dexame NCT01415882 · Phase 2 · registry result, not featured evidence · combination —Arm C (Higher-dose Ixazomib Citrat NCT01415882 · Phase 2 · registry result, not featured evidence · combination —Arm D (Ixazomib Citrate, Dexametha NCT01415882 · Phase 2 · registry result, not featured evidence · combination —Arm E (Ixazomib Citrate, Cyclophos NCT01415882 · Phase 2 · registry result, not featured evidence · combination 0%Ixazomib Combination Therapy NCT02924272 · Phase 2 · registry result, not featured evidence · combination 13%Ixazomib Monotherapy NCT02924272 · Phase 2 · registry result, not featured evidence · monotherapy 15%Arm I (Ixazomib Citrate, Lenalidom NCT02389517 · Phase 2 · registry result, not featured evidence · combination 4.5%Arm II (Lenalidomide) NCT02389517 · Phase 2 · registry result, not featured evidence — NCT02412228 · Phase 2 · registry result, not featured evidence · combination —Arm A (Ixazomib and Dexamethasone) NCT02765854 · Phase 2 · registry result, not featured evidence —Arm B (Ixazomib and Dexamethasone) NCT02765854 · Phase 2 · registry result, not featured evidence —Arm C (Ixazomib, Dexamethasone, Le NCT02765854 · Phase 2 · registry result, not featured evidence · combination —4 mg NCT03170882 · Phase 2 · registry result, not featured evidence · combination — NCT02440464 · Phase 2 · registry result, not featured evidence 32.4%4 mg + 25 mg + 40 mg NCT02917941 · Phase 2 · registry result, not featured evidence · combination —4 mg NCT02168101 · Phase 2 · registry result, not featured evidence —3 mg NCT02168101 · Phase 2 · registry result, not featured evidence —2.3 mg NCT02168101 · Phase 2 · registry result, not featured evidence 22.2%Ixazomib 4.0 mg + CYC 300 mg/m^2 + NCT02046070 · Phase 2 · registry result, not featured evidence · combination 21.8%Ixazomib 4.0 mg + CYC 300 mg/m^2 + NCT02046070 · Phase 2 · registry result, not featured evidence · combination 29.4%Ixazomib 4.0 mg + CYC 400 mg/m^2 + NCT02046070 · Phase 2 · registry result, not featured evidence · combination — NCT02499081 · Phase 2 · registry result, not featured evidence —4 mg NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination —3 mg NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination —90 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination —90 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination —80 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination —80 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination —70 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination —70 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination |
| Serious AEs | 56.8%a NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3 show 40 more results—Ixazomib + LenDex NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 65.4%Ixazomib + LenDex (Exposure ≥19 Cy NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 73%Ixazomib+ LenDex (Exposure Up to 1 NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 — NCT03941860 · Phase 3 · combination · Multiple Myeloma · phase 3 27.4% NCT02181413 · Phase 3 23.7% NCT02312258 · Phase 3 37.8% NCT03416374 · Phase 4 · registry result, not featured evidence · combination 31.4% NCT03748953 · Phase 3 · registry result, not featured evidence 13.3% NCT02619682 · Phase 2 · registry result, not featured evidence 48.5%Arm A (Ixazomib Citrate and Dexame NCT01415882 · Phase 2 · registry result, not featured evidence · combination 31.4%Arm B (Ixazomib Citrate and Dexame NCT01415882 · Phase 2 · registry result, not featured evidence · combination 31.4%Arm C (Higher-dose Ixazomib Citrat NCT01415882 · Phase 2 · registry result, not featured evidence · combination 38.9%Arm D (Ixazomib Citrate, Dexametha NCT01415882 · Phase 2 · registry result, not featured evidence · combination 58.3%Arm E (Ixazomib Citrate, Cyclophos NCT01415882 · Phase 2 · registry result, not featured evidence · combination 44.4%Ixazomib Combination Therapy NCT02924272 · Phase 2 · registry result, not featured evidence · combination 52.2%Ixazomib Monotherapy NCT02924272 · Phase 2 · registry result, not featured evidence · monotherapy 25%Arm I (Ixazomib Citrate, Lenalidom NCT02389517 · Phase 2 · registry result, not featured evidence · combination 9.1%Arm II (Lenalidomide) NCT02389517 · Phase 2 · registry result, not featured evidence 8.3% NCT02412228 · Phase 2 · registry result, not featured evidence · combination 74.1%Arm A (Ixazomib and Dexamethasone) NCT02765854 · Phase 2 · registry result, not featured evidence 45.5%Arm B (Ixazomib and Dexamethasone) NCT02765854 · Phase 2 · registry result, not featured evidence 47.6%Arm C (Ixazomib, Dexamethasone, Le NCT02765854 · Phase 2 · registry result, not featured evidence · combination 55.6%4 mg NCT03170882 · Phase 2 · registry result, not featured evidence · combination 52.4% NCT02440464 · Phase 2 · registry result, not featured evidence 35.3%4 mg + 25 mg + 40 mg NCT02917941 · Phase 2 · registry result, not featured evidence · combination 66.7%4 mg NCT02168101 · Phase 2 · registry result, not featured evidence 66.7%3 mg NCT02168101 · Phase 2 · registry result, not featured evidence 0%2.3 mg NCT02168101 · Phase 2 · registry result, not featured evidence 47.2%Ixazomib 4.0 mg + CYC 300 mg/m^2 + NCT02046070 · Phase 2 · registry result, not featured evidence · combination 38.5%Ixazomib 4.0 mg + CYC 300 mg/m^2 + NCT02046070 · Phase 2 · registry result, not featured evidence · combination 58.8%Ixazomib 4.0 mg + CYC 400 mg/m^2 + NCT02046070 · Phase 2 · registry result, not featured evidence · combination 40% NCT02499081 · Phase 2 · registry result, not featured evidence 44%4 mg NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination 57.1%3 mg NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination 0%90 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination —90 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination 42.1%80 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination —80 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination 66.7%70 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination —70 mg/m^2 NCT02477215 · Phase 1/2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | a diarrhoea 51.5% (placebo 42.6%) constipation 34.6% (placebo 27.6%) anaemia 34.1% (placebo 29.2%) NCT01564537 · Phase 3 · combination · Multiple Myeloma · phase 3 show 32 more resultsdiarrhoea 77% (placebo 30%) oedema peripheral 55.5% (placebo 32.5%) constipation 48.2% (placebo 38.1%) NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 diarrhoea 41.7% (placebo 30%) oedema peripheral 40.5% (placebo 32.5%) constipation 36.2% (placebo 38.1%) NCT01850524 · Phase 3 · combination · Multiple Myeloma · phase 3 nausea 39.1% (placebo 15.4%) diarrhoea 34.3% (placebo 23.6%) arthralgia 26.6% (placebo 16.6%) NCT02181413 · Phase 3 nausea 27.9% (placebo 8.3%) diarrhoea 23.9% (placebo 12.7%) vomiting 23.9% (placebo 4%) NCT02312258 · Phase 3 diarrhoea 28.9% white blood cell count decreased 24.4% platelet count decreased 20% NCT03416374 · Phase 4 · registry result, not featured evidence · combination upper respiratory tract infection 40% (placebo 25%) diarrhoea 34.3% (placebo 25%) vomiting 25.7% (placebo 0%) NCT03748953 · Phase 3 · registry result, not featured evidence lymphocyte decreased 36.7% lymphocyte decreased 33.3% wbc decreased 33.3% NCT02619682 · Phase 2 · registry result, not featured evidence fatigue 87.9% nausea 84.8% platelet count decreased 81.8% NCT01415882 · Phase 2 · registry result, not featured evidence · combination fatigue 94.3% peripheral sensory neuropathy 88.6% platelet count decreased 74.3% NCT01415882 · Phase 2 · registry result, not featured evidence · combination fatigue 82.9% platelet count decreased 80% peripheral sensory neuropathy 77.1% NCT01415882 · Phase 2 · registry result, not featured evidence · combination fatigue 94.4% diarrhea 80.6% nausea 77.8% NCT01415882 · Phase 2 · registry result, not featured evidence · combination anemia 91.7% fatigue 91.7% lymphocyte count decreased 91.7% NCT01415882 · Phase 2 · registry result, not featured evidence · combination anaemia 33.3% upper respiratory tract infection 33.3% aspartate aminotransferase increased 22.2% NCT02924272 · Phase 2 · registry result, not featured evidence · combination hypertension 17.4% upper respiratory tract infection 13% ankle fracture 8.7% NCT02924272 · Phase 2 · registry result, not featured evidence · monotherapy diarrhea 95% fatigue 50% nausea 50% NCT02389517 · Phase 2 · registry result, not featured evidence · combination diarrhea 50% fatigue 40.9% upper respiratory infection 27.3% NCT02389517 · Phase 2 · registry result, not featured evidence platelet count decreased 91.7% lymphocyte count decreased 83.3% rash 83.3% NCT02412228 · Phase 2 · registry result, not featured evidence · combination pneumonia 33.3% colitis 22.2% upper respiratory infection 22.2% NCT02765854 · Phase 2 · registry result, not featured evidence conjunctivits 36.4% bone pain 18.2% pneumonia 18.2% NCT02765854 · Phase 2 · registry result, not featured evidence thrombocytopenia 42.9% neutropenia 19% pneumonia 19% NCT02765854 · Phase 2 · registry result, not featured evidence · combination 4 mg diarrhoea 38.9% peripheral sensory neuropathy 26.4% fatigue 23.6% NCT03170882 · Phase 2 · registry result, not featured evidence · combination pyrexia 14.3% (placebo 4.5%) myalgia 4.8% (placebo 0%) upper respiratory tract infection 4.8% (placebo 0%) NCT02440464 · Phase 2 · registry result, not featured evidence 4 mg + 25 mg + 40 mg constipation 50% upper respiratory tract infection 47.1% diarrhoea 41.2% NCT02917941 · Phase 2 · registry result, not featured evidence · combination 4 mg thrombocytopenia 100% anaemia 66.7% aspartate aminotransferase increased 66.7% NCT02168101 · Phase 2 · registry result, not featured evidence 3 mg gastritis 66.7% thrombocytopenia 66.7% abdominal pain 33.3% NCT02168101 · Phase 2 · registry result, not featured evidence 2.3 mg diarrhoea 100% dry eye 66.7% hypertension 66.7% NCT02168101 · Phase 2 · registry result, not featured evidence anaemia 30.6% diarrhoea 30.6% upper respiratory tract infection 25% NCT02046070 · Phase 2 · registry result, not featured evidence · combination diarrhoea 33.3% upper respiratory tract infection 26.9% anaemia 24.4% NCT02046070 · Phase 2 · registry result, not featured evidence · combination neutropenia 47.1% anaemia 32.4% nausea 29.4% NCT02046070 · Phase 2 · registry result, not featured evidence · combination hyperglycemia 85% hypoalbuminemia 80% fatigue 75% NCT02499081 · Phase 2 · registry result, not featured evidence 4 mg anemia 76% platelet count decreased 76% neutrophil count decreased 68% NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination 3 mg anemia 85.7% lymphocyte count decreased 85.7% white blood cell decreased 85.7% NCT02119468 · Phase 1/2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for 36 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ixazomib
show 7 more results
show 8 more results
show 3 more results
show 1 more result
show 3 more results
show 4 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 150 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ixazomib's landscape · TQB3602's landscape